Table 2.
Effects | Mechanisms | References |
---|---|---|
Anti-inflammation | Inhibiting the TNF-α, IL-1β, and NO | [10] |
Increasing the IL-6 and IL-10 | [35] | |
Inhibiting the iNOS, NF-κB, ERK, and p38 MAPK pathways | [36] | |
| ||
Antioxidation | Activation of cysteine/glutamate antiporter | [46] |
Activation of γ-GCS | (Kimura and [43]) | |
Cooperating with HO, SOD, and Nrf2 antioxidative system | (Kimura and [43]) | |
Decreasing the production of the prooxidase | (Kimura and [43]) | |
| ||
Antiapoptosis | Inhibiting the H2O2-activated calcium pathways | [53] |
Reducing caspase-3 and increasing Bcl-2 | [54] | |
Regulating the NF-κB signaling pathway | [57] | |
| ||
Regulating autophagy-dependent cell death | Reducing Beclin-1 and LC-3 LC3-positive cells were partly colocalized with PI |
[1] [8] [63] [51] |
| ||
Vasodilation | Activating the KATP channels (CSE-generated H2S) Liberating NO from S-nitrosothiols |
[65] [78] |
| ||
Ca2+ modulation | Activating the L-type Ca2+ channels | [68] |
Inducing Ca2+ waves | [70] | |
| ||
Attenuating edema | Alleviating BBB disruption and reducing AQP4 expression | [72] |
| ||
Facilitating LTP | Potentiating the NMDA receptor | [77] |
| ||
Antiexcitotoxicity | Reducing glutamate release after TBI | [64] |